Menu
Back to User profile » Prof. Dr. Ivo Abraham
Papers published by Prof. Dr. Ivo Abraham:
Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
Leys AM, Ramboer E, Favreau M, Denhaerynck K, MacDonald K, Abraham I, Brié H
Clinical Ophthalmology 2020, 14:1473-1481
Published Date: 2 June 2020
Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment
Al Yami MS, Kurdi S, Abraham I
Journal of Blood Medicine 2018, 9:25-34
Published Date: 21 February 2018
Clinical efficacy and safety of Zarzio® (EP2006), a biosimilar recombinant human granulocyte colony-stimulating factor
Tharmarajah S, Mohammed A, Bagalagel A, MacDonald K, Abraham I
Biosimilars 2014, 4:1-9
Published Date: 12 March 2014
Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor
Bagalagel A, Mohammed A, MacDonald K, Abraham I
Biosimilars 2013, 3:55-62
Published Date: 27 August 2013
Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia
Mohammed A, Bagalagel A, MacDonald K, Abraham I
Biosimilars 2013, 3:45-53
Published Date: 27 August 2013
Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia
Bagalagel A, Mohammed A, MacDonald K, Abraham I
Biosimilars 2013, 3:35-43
Published Date: 21 August 2013
Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia
Abraham I, MacDonald K
Biosimilars 2012, 2:13-25
Published Date: 6 September 2012
Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program
Abraham I, MacDonald K, Hermans C, Aerts A, Lee C, Brié H, Vancayzeele S
Vascular Health and Risk Management 2011, 7:209-235
Published Date: 31 March 2011